Marked intra- and inter-patient variability of itraconazole steady state plasma concentrations

Therapie

Volumn 51, Issue 2, 1996, Pages 163-167

  Poirier, J M ^a   Berlioz, F ^a   Isnard, F ^a   Cheymol, G ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Intra and inter subject variability; Itraconazole; Neutropenic patient; Therapeutic drug monitoring

Indexed keywords

DRUG METABOLITE; ITRACONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ASPERGILLOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; LYMPHOMA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; ASPERGILLOSIS; FOLLOW-UP STUDIES; HUMANS; INDIVIDUALITY; ITRACONAZOLE; MIDDLE AGED; NEUTROPENIA; TIME FACTORS;

EID: 0029994005     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Van Custen J, Van Gerven F, Janssen PAJ. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis 1987; 9: 15-32.
2. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990; 23: 607-614.
3. Van't Wout JW, Novakova I, Verhagen CAH et al. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B.J Infect 1991; 22: 45-52.
4. Van Peer A, Woestenborghs R, Heykants J et al. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989; 36: 423-426.
5. Heykants J, Van Peer A, Van de Velde V et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32: 67-87.
6. Van Custen. The in vitro antifungal spectrum of itraconazole. Mycoses 1989; 32: 7-13.
7. Persat F, Marzullo C, Guyotat D et al. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 1992; 28: 838-841.
8. Poirier JM, Lebot M, Descamps P et al. Determination of itraconazole and its active metabolite in plasma by column liquid chromatography. Ther Drug Monit 1994; 16: 596-601.
9. Hardin TC, Graybill JR, Fetchick R et al. Pharmacokinetics of itraconazole following oral absorption to normal volunteers. Antimicrob Agents Chemother 1988; 32: 1310-1313.
10. Boogaerts MA, Verhoef GE, Zachee P et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32: 103-108.
11. Bradford CR, Prentice AG, Warnock DW, Copplestone JA. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. J Antimicrob Chemother 1991; 28: 555-560.
12. Remmel RP, Dombrovskis D, Canafax DM. Assay of itraconazole in leukemic patient plasma by reversed-phase small bore liquid chromatography. J Chromatogr Biomed Appl 1988; 432: 388-394.
13. Smith D, Van de Velde V, Woestenborghs R et al. The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol 1992; 44: 618-619.
14. Shaw MT, Spector MH, Ladman AJ. Effects of cancer, radiotherapy and cytotoxic drugs on intestinal stucture and function. Cancer Treatment Review 1979; 6: 141-151.
15. Hay R, Clayton Y, Moore M et al An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988; 119; 359-366.
16. 2 receptor antagonists on the pharmacokinetics of itraconazole, a new oral antifungal. Br J Clin Pharmacol 1988; 27, 105P-106P.